XTANDI® Receives FDA Approval for Earlier Prostate Cancer Treatment, Expanding its Reach in the Fight Against the Disease
November 17, 2023 : Pfizer and Astellas Pharma Inc. have announced the U.S. Food and Drug Administration (FDA) approval of XTANDI® (enzalutamide) for the treatment of patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) with a high risk of metastasis.
NYU Langone Health and Philips Join Forces to Elevate Patient Care through Cutting-Edge Technology
November 17, 2023 : NYU Langone Health, a leading academic healthcare system with a global reputation for excellence in clinical care, research, and education, has announced a multi-year partnership with Philips, a global leader in health technology.
